![Bernd Winterhalter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bernd Winterhalter
Corporate Officer/Principal en
CureVac SE
.
Perfil
Bernd Winterhalter is currently the Chief Development Officer at CureVac SE since 2019.
Prior to this, he worked as the Executive Medical Director at Bristol-Myers Squibb GmbH & Co. KGaA from 2004 to 2018 and as the Vice President-Medical, Science & Health Economics at Pharmacia GmbH from 1997 to 2003.
He also briefly served as the Chief Development Officer at CureVac NV from 2019 to 2021.
Dr. Winterhalter holds a doctorate degree from the University of Freiburg.
Cargos activos de Bernd Winterhalter
| Empresas | Cargo | Inicio |
|---|---|---|
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Corporate Officer/Principal | 01/12/2019 |
Antiguos cargos conocidos de Bernd Winterhalter.
| Empresas | Cargo | Fin |
|---|---|---|
| CUREVAC | Corporate Officer/Principal | 01/02/2021 |
Bristol-Myers Squibb GmbH & Co. KGaA
 Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical medicines | Director Técnico/Científico/I+D | 01/01/2018 |
Pharmacia GmbH | Director Técnico/Científico/I+D | 01/01/2003 |
Formación de Bernd Winterhalter.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
11
Relaciones de 1er grado
5
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
University of Freiburg
 University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmacia GmbH | |
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical medicines | Health Technology |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
- Bolsa de valores
- Insiders
- Bernd Winterhalter
